Embracing Personalized Strategies in Radiotherapy for Nasopharyngeal Carcinoma: Beyond the Conventional Bounds of Fields and Borders
- PMID: 38254872
- PMCID: PMC10814653
- DOI: 10.3390/cancers16020383
Embracing Personalized Strategies in Radiotherapy for Nasopharyngeal Carcinoma: Beyond the Conventional Bounds of Fields and Borders
Abstract
Radiotherapy is the primary treatment modality for non-metastatic nasopharyngeal carcinoma (NPC) across all TN-stages. Locoregional control rates have been impressive even from the 2D radiotherapy (RT) era, except when the ability to deliver optimal dose coverage to the tumor is compromised. However, short- and long-term complications following head and neck RT are potentially debilitating, and thus, there has been much research investigating technological advances in RT delivery over the past decades, with the primary goal of limiting normal tissue damage. On this note, with a plateau in gains of therapeutic ratio by modern RT techniques, future advances have to be focused on individualization of RT, both in terms of dose prescription and the delineation of target volumes. In this review, we analyzed the guidelines and evidence related to contouring methods, and dose prescription for early and locoregionally advanced (LA-) NPC. Next, with the preference for induction chemotherapy (IC) in patients with LA-NPC, we assessed the evidence concerning radiotherapy adaptations guided by IC response, as well as functional imaging and contour changes during treatment. Finally, we discussed on RT individualization that is guided by EBV DNA assessment, and its importance in the era of combinatorial immune checkpoint blockade therapy with RT.
Keywords: nasopharyngeal carcinoma; radiotherapy; response adaptation; toxicity; treatment individualization.
Conflict of interest statement
Melvin L.K. Chua reports personal fees from Astellas, Janssen, Bayer, Pfizer, BeiGene, MSD, Varian, IQVIA, Telix Pharmaceuticals, personal fees and non-financial support from AstraZeneca, non-financial support from Decipher Biosciences, non-financial support from MedLever, consults for immunoSCAPE Inc., and is a co-inventor of the patent of a High Sensitivity Lateral Flow Immunoassay For Detection of Analyte in Sample (10202107837T), Singapore and serves on the Board of Directors of Digital Life Line Pte Ltd. that owns the licensing agreement of the patent, outside the submitted work. PL Yip, R You, and MY Chen declared no conflicts of interest.
Similar articles
-
Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.Oncotarget. 2017 Feb 21;8(8):14078-14088. doi: 10.18632/oncotarget.13285. Oncotarget. 2017. PMID: 27845907 Free PMC article.
-
Association of Treatment Advances With Survival Rates in Pediatric Patients With Nasopharyngeal Carcinoma in China, 1989-2020.JAMA Netw Open. 2022 Mar 1;5(3):e220173. doi: 10.1001/jamanetworkopen.2022.0173. JAMA Netw Open. 2022. PMID: 35234882 Free PMC article.
-
Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy After Induction Chemotherapy in Stages II-IVb Nasopharyngeal Carcinoma.Front Oncol. 2020 Nov 9;10:539321. doi: 10.3389/fonc.2020.539321. eCollection 2020. Front Oncol. 2020. PMID: 33240805 Free PMC article.
-
Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma.Chin Clin Oncol. 2018 Apr;7(2):15. doi: 10.21037/cco.2018.04.05. Chin Clin Oncol. 2018. PMID: 29764160 Review.
-
Advances in systemic treatment for nasopharyngeal carcinoma.Chin Clin Oncol. 2016 Apr;5(2):21. doi: 10.21037/cco.2016.03.03. Chin Clin Oncol. 2016. PMID: 27121881 Review.
Cited by
-
The impact of different cervical planning target volume designs on efficacy and toxicity in nasopharyngeal carcinoma: a single-center retrospective study.BMC Cancer. 2025 Mar 17;25(1):485. doi: 10.1186/s12885-025-13865-y. BMC Cancer. 2025. PMID: 40091010 Free PMC article.
-
Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival.JCO Precis Oncol. 2025 Jan;9:e2400603. doi: 10.1200/PO-24-00603. Epub 2025 Jan 7. JCO Precis Oncol. 2025. PMID: 39772833 Free PMC article.
-
Microbiota and metabolomic profiling coupled with machine learning to identify biomarkers and drug targets in nasopharyngeal carcinoma.Front Pharmacol. 2025 Feb 26;16:1551411. doi: 10.3389/fphar.2025.1551411. eCollection 2025. Front Pharmacol. 2025. PMID: 40078290 Free PMC article.
-
The clinical value of FAPI PET/CT in delineating target volumes for nasopharyngeal carcinoma.Eur J Nucl Med Mol Imaging. 2025 May 31. doi: 10.1007/s00259-025-07347-3. Online ahead of print. Eur J Nucl Med Mol Imaging. 2025. PMID: 40447840
-
Individualization of clinical target volume delineation in eccentric nasopharyngeal carcinoma: a prospective comparative study.Front Oncol. 2025 Aug 4;15:1587764. doi: 10.3389/fonc.2025.1587764. eCollection 2025. Front Oncol. 2025. PMID: 40831921 Free PMC article.
References
-
- Amin M.B., Edge S.B., Greene F.L., Byrd D.R., Brookland R.K., Washington M.K., Gershenwald J.E., Compton C.C., Hess K.R., Sullivan D.C. AJCC Cancer Staging Manual. Springer International Publishing; Berlin/Heidelberg, Germany: 2018.
-
- Huang S.H., Jacinto J.C.K., O’Sullivan B., Su J., Kim J., Ringash J., Spreafico A., Yu E., Perez-Ordonez B., Weinreb I., et al. Clinical presentation and outcome of human papillomavirus-positive nasopharyngeal carcinoma in a North American cohort. Cancer. 2022;128:2908–2921. doi: 10.1002/cncr.34266. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous